Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance

Completed

• Conditions: Bacterial Infections

• Registration Number: NCT01788449
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.

Detailed Description

Primarily, this study is designed to assess the efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of extended-spectrum betalactamases (ESBLs) producing E.coli or K pneumoniae, S aureus methicillin resistant (MRSA) and Enterococcus vancomycin resistant (VRE). Secondly, this study plans to determine the acquisition rate of ESBL producing E Coli or K pneumoniae, methicillin resistant S Aureus (MRSA) and vancomycin resistant Enterococcus spp (VRE), both pre- and post-intervention.

Study Timeline

• Study Start: 2005-05
• Primary Completion: 2007-02
• Study Completion: 2007-02
• Study First Submitted: 2009-08-06
• Status Verified: 2013-02
• Study First Submitted QC: 2013-02-07
• Study First Posted: 2013-02-11
• Last Update Submitted: 2013-02-12
• Last Update Posted: 2013-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 335

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Endpoints will be efficacy of piperacillin/tazobactam in reducing colonization rates and infection of E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus	8 months

Secondary Outcome Measures

Name	Time	Method
Endpoints will be acquisition and infection rate of ESBL producing E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus	8 months